Chicago Equity Partners LLC increased its holdings in shares of Inogen, Inc (NASDAQ:INGN) by 17.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,125 shares of the medical technology company’s stock after purchasing an additional 2,370 shares during the period. Chicago Equity Partners LLC owned approximately 0.08% of Inogen worth $1,533,000 at the end of the most recent quarter.
Several other large investors have also added to or reduced their stakes in the company. Adams Diversified Equity Fund Inc. bought a new position in shares of Inogen during the 3rd quarter valued at about $618,000. Crossmark Global Holdings Inc. bought a new position in shares of Inogen during the 3rd quarter valued at about $330,000. Nationwide Fund Advisors lifted its holdings in shares of Inogen by 2.5% during the 3rd quarter. Nationwide Fund Advisors now owns 80,007 shares of the medical technology company’s stock valued at $7,609,000 after purchasing an additional 1,950 shares in the last quarter. Strs Ohio lifted its holdings in shares of Inogen by 4,476.0% during the 3rd quarter. Strs Ohio now owns 22,880 shares of the medical technology company’s stock valued at $2,175,000 after purchasing an additional 22,380 shares in the last quarter. Finally, Curbstone Financial Management Corp lifted its holdings in shares of Inogen by 87.9% during the 3rd quarter. Curbstone Financial Management Corp now owns 22,460 shares of the medical technology company’s stock valued at $2,136,000 after purchasing an additional 10,505 shares in the last quarter.
Several equities analysts have recently weighed in on the company. BidaskClub cut Inogen from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Needham & Company LLC reiterated a “buy” rating and set a $108.00 price objective on shares of Inogen in a report on Friday, September 1st. Leerink Swann reiterated an “outperform” rating and set a $120.00 price objective (up previously from $115.00) on shares of Inogen in a report on Wednesday, November 8th. Zacks Investment Research cut Inogen from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 8th. Finally, Piper Jaffray Companies reiterated a “hold” rating and set a $90.00 price objective on shares of Inogen in a report on Tuesday, September 12th. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $103.14.
Shares of Inogen, Inc (NASDAQ:INGN) opened at $117.37 on Tuesday. The company has a market capitalization of $2,383.19, a P/E ratio of 92.84, a price-to-earnings-growth ratio of 4.80 and a beta of 0.99. Inogen, Inc has a 12 month low of $60.02 and a 12 month high of $124.90.
Inogen (NASDAQ:INGN) last released its earnings results on Tuesday, November 7th. The medical technology company reported $0.33 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.29 by $0.04. The firm had revenue of $69.00 million for the quarter, compared to analysts’ expectations of $63.55 million. Inogen had a return on equity of 13.37% and a net margin of 11.36%. The business’s quarterly revenue was up 26.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.25 EPS. equities analysts forecast that Inogen, Inc will post 1.19 earnings per share for the current year.
In other Inogen news, EVP Matt Scribner sold 2,500 shares of the business’s stock in a transaction that occurred on Friday, August 18th. The stock was sold at an average price of $92.45, for a total value of $231,125.00. Following the sale, the executive vice president now owns 6,964 shares in the company, valued at approximately $643,821.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Raymond Huggenberger sold 14,000 shares of the business’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $94.07, for a total value of $1,316,980.00. Following the completion of the sale, the director now owns 7,808 shares in the company, valued at approximately $734,498.56. The disclosure for this sale can be found here. Insiders sold a total of 53,000 shares of company stock worth $5,140,630 in the last 90 days. Company insiders own 5.31% of the company’s stock.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.